Evidence method
Level · gp.fundamentals.debt_to_revenue
134.46% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANIP · Sep 30, 2019
ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001104659-19-060283General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
2.97% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
42.45% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
1.25% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
89.94% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
70.78% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
14.27% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
9.70% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
4.81% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 128.48%
- Current
- 134.46%
- Delta
- 5.98%
- Previous
- 3.01%
- Current
- 2.97%
- Delta
- -0.04%
- Previous
- 8.73%
- Current
- 42.45%
- Delta
- 33.72%
- Previous
- 15.00%
- Current
- 1.25%
- Delta
- -13.75%
- Previous
- 83.33%
- Current
- 89.94%
- Delta
- 6.61%
- Previous
- 71.24%
- Current
- 70.78%
- Delta
- -0.46%
- Previous
- 17.09%
- Current
- 14.27%
- Delta
- -2.82%
- Previous
- 10.62%
- Current
- 9.70%
- Delta
- -0.92%
- Previous
- 4.77%
- Current
- 4.81%
- Delta
- 0.04%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ANIP Fundamental State →Has State · ANI PHARMACEUTICALS INC →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · ANIP CAPEX_INTENSITY_DECREASED →Transitioned To · ANIP CASH_GENERATION_INCREASED →Transitioned To · ANIP GROWTH_DECREASED →Transitioned To · ANIP INVENTORY_PRESSURE_INCREASED →Transitioned To · ANIP MARGIN_DECREASED →Transitioned To · ANIP PROFITABILITY_DECREASED →Transitioned To · ANIP R_AND_D_INTENSITY_DECREASED →Transitioned To · ANIP SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.